1921
Volume 98, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Schistosomiasis remains a major public health problem in Kenya. The World Health Organization recommends preventive chemotherapy with praziquantel (PZQ) to control morbidity due to schistosomiasis. Morbidity is considered linked to intensity of infection, which along with prevalence is used to determine the frequency of mass drug administration (MDA) to school-age children. We determined the impact of annual school-based MDA on children across all primary and high school years using a repeated cross-sectional study design in five schools near Lake Victoria in western Kenya, an area endemic for . At baseline and for the following four consecutive years, between 897 and 1,440 school children in Grades 1–12 were enrolled and evaluated by Kato-Katz for and soil-transmitted helminths (STH), followed by annual MDA with PZQ and albendazole. Four annual rounds of MDA with PZQ were associated with reduced prevalence in all school children (44.7–14.0%; < 0.001) and mean intensity of infection by 91% (90.4 to 8.1 eggs per gram [epg] of stool; < 0.001). Prevalence of high-intensity infection (≥ 400 epg) decreased from 6.8% at baseline to 0.3% by the end of the study. Soil-transmitted helminth infections, already low at baseline, also decreased significantly over the years. In this high prevalence area, annual school-based MDA with high coverage across all Grades (1–12) resulted in rapid and progressive declines in overall prevalence and intensity of infection. This decrease was dramatic in regard to heavy infections in older school-attending children.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.17-0908
2018-05-09
2018-11-20
Loading full text...

Full text loading...

/deliver/fulltext/14761645/98/5/tpmd170908.html?itemId=/content/journals/10.4269/ajtmh.17-0908&mimeType=html&fmt=ahah

References

  1. Colley DG, Bustinduy AL, Secor WE, King CH, , 2014. Human schistosomiasis. Lancet 383: 22532264.
  2. WHO, 2012. Preventive Chemotherapy Databank. Geneva, Switzerland: Word Health Organization.
  3. van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JD, Engels D, , 2003. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop 86: 125139.
  4. WHO, 2013. Schistosomiasis: number of people treated in 2011. Wkly Epidemiol Rec 88: 8188.
  5. GAHI, 2010. Global Atlas of Helminths Infection. Available at: http://www.thiswormyworld.org/maps/kenya. Accessed October 24, 2017.
  6. Handzel T, Karanja DM, Addiss DG, Hightower AW, Rosen DH, Colley DG, Andove J, Slutsker L, Secor WE, , 2003. Geographic distribution of schistosomiasis and soil-transmitted helminths in western Kenya: implications for anthelminthic mass treatment. Am J Trop Med Hyg 69: 318323.
  7. Woodhall DM, Wiegand RE, Wellman M, Matey E, Abudho B, Karanja DM, Mwinzi PM, Montgomery SP, Secor WE, , 2013. Use of geospatial modeling to predict Schistosoma mansoni prevalence in Nyanza Province, Kenya. PLoS One 8: e71635.
  8. WHO, 2002. Prevention and control of schistosomiasis and soil-transmitted helminthiasis: report of a WHO expert committee. WHO Tech Rep Ser 912: 157.
  9. Kabatereine NB, Brooker S, Koukounari A, Kazibwe F, Tukahebwa EM, Fleming FM, Zhang Y, Webster JP, Stothard JR, Fenwick A, , 2007. Impact of a national helminth control programme on infection and morbidity in Ugandan schoolchildren. Bull World Health Organ 85: 9199.
  10. Koukounari A, Gabrielli AF, Toure S, Bosque-Oliva E, Zhang Y, Sellin B, Donnelly CA, Fenwick A, Webster JP, , 2007. Schistosoma haematobium infection and morbidity before and after large-scale administration of praziquantel in Burkina Faso. J Infect Dis 196: 659669.
  11. Mwinzi PN, Montgomery SP, Owaga CO, Mwanje M, Muok EM, Ayisi JG, Laserson KF, Muchiri EM, Secor WE, Karanja DM, , 2012. Integrated community-directed intervention for schistosomiasis and soil transmitted helminths in western Kenya—a pilot study. Parasit Vectors 5: 182.
  12. Richter J, , 2003. The impact of chemotherapy on morbidity due to schistosomiasis. Acta Trop 86: 161183.
  13. WHO, 2013. Schistosomiasis: Progress Report 2001–2011, Strategic Plan 2012–2020. Geneva, Switzerland: World Health Organization.
  14. Phillips-Howard PA, 2003. The efficacy of permethrin-treated bed nets on child mortality and morbidity in western Kenya I. Development of infrastructure and description of study site. Am J Trop Med Hyg 68: 39.
  15. Black CL, Muok EM, Mwinzi PN, Carter JM, Karanja DM, Secor WE, Colley DG, , 2010. Increases in levels of schistosome-specific immunoglobulin E and CD23(+) B cells in a cohort of Kenyan children undergoing repeated treatment and reinfection with Schistosoma mansoni. J Infect Dis 202: 399405.
  16. WHO, 1994. Bench Aids for the Diagnosis of Intestinal Parasites. Geneva, Switzerland: World Health Organization.
  17. WHO Expert Committee, 2002. Prevention and control of schistosomiasis and soil transmitted helminthiasis. World Health Organ Tech Rep Ser 912: ivi, 1–57 back cover.
  18. King CH, Dangerfield-Cha M, , 2008. The unacknowledged impact of chronic schistosomiasis. Chronic Illn 4: 6579.
  19. King CH, Dickman K, Tisch DJ, , 2005. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 365: 15611569.
  20. Odiere MR, Rawago FO, Ombok M, Secor WE, Karanja DM, Mwinzi PN, Lammie PJ, Won K, , 2012. High prevalence of schistosomiasis in Mbita and its adjacent islands of Lake Victoria, western Kenya. Parasit Vectors 5: 278.
  21. Opisa S, Odiere MR, Jura WG, Karanja DM, Mwinzi PN, , 2011. Faecal contamination of public water sources in informal settlements of Kisumu City, western Kenya. Water Sci Technol 66: 26742681.
  22. Sang HC, Muchiri G, Ombok M, Odiere MR, Mwinzi PN, , 2014. Schistosoma haematobium hotspots in south Nyanza, western Kenya: prevalence, distribution and co-endemicity with Schistosoma mansoni and soil-transmitted helminths. Parasit Vectors 7: 125.
  23. Karanja DM, Hightower AW, Colley DG, Mwinzi PN, Galil K, Andove J, Secor WE, , 2002. Resistance to reinfection with Schistosoma mansoni in occupationally exposed adults and effect of HIV-1 co-infection on susceptibility to schistosomiasis: a longitudinal study. Lancet 360: 592596.
  24. Woolhouse ME, Hagan P, , 1999. Seeking the ghost of worms past. Nat Med 5: 12251227.
  25. Secor WE, Montgomery SP, , 2015. Something old, something new: is praziquantel enough for schistosomiasis control? Future Med Chem 7: 681684.
  26. Karanja DMS, Awino EK, Wiegand RE, Okoth E, Abudho BO, Mwinzi PNM, Montgomery SP, Secor WE, , 2017. Cluster randomized trial comparing school-based mass drug administration schedules in areas of western Kenya with moderate initial prevalence of Schistosoma mansoni infections. PLoS Negl Trop Dis 11: e0006033.
  27. Onkanga IO, Mwinzi PN, Muchiri G, Andiego K, Omedo M, Karanja DM, Wiegand RE, Secor WE, Montgomery SP, , 2016. Impact of two rounds of praziquantel mass drug administration on Schistosoma mansoni infection prevalence and intensity: a comparison between community wide treatment and school based treatment in western Kenya. Int J Parasitol 46: 439445.
  28. WHO, 2006. Preventive chemotherapy. Human helminthiasis: Coordinated Use of Anthelminthic Drugs in Interventions: A Manual for Health Professionals and Programme Managers. Geneva, Switzerland: World Health Organization.
  29. WHO, 2001. Resolution on Schistosomiasis and Soil Transmitted Helminth Infections. WHA 54.19. Available: http://www.who.int/neglected_diseases/mediacentre/WHA_54.19_Eng.pdf. Accessed October 14, 2017.
  30. WHO, 2012. Schistosomiasis Progress Report. 2001–2011 and Strategic Plan 2012–2020. Geneva, Switzerland: World Health Organization.
  31. WHO, 2012. WHA 65.21. Elimination of schistosomiasis. Sixty-fifth World Health Assembly Geneva May 21–26, 2012 Resolutions, Decisions and Annexes. Geneva, Switzerland: World Health Organization, 36–37.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.17-0908
Loading
/content/journals/10.4269/ajtmh.17-0908
Loading

Data & Media loading...

  • Received : 21 Nov 2017
  • Accepted : 05 Jan 2018

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error